Corporate Presentation | September 2020 Forward-Looking Statements

These materials have been prepared by Ichnos Sciences which the Company will operate in the future and must be not been independently verified and is subject to verification, (“Ichnos” or “the Company”) solely for informational purposes read together with such assumptions. Predictions, projections, completion, and change without notice. The information and are strictly confidential and may not be taken away, or forecasts of the economy or economic trends of the contained in these materials is current as of the date hereof reproduced, or redistributed to any other person. This markets are not necessarily indicative of the future or likely and is subject to change without notice, and its accuracy is not presentation is on drugs in clinical development and includes performance of the Company, and the forecast financial guaranteed. Accordingly, no representation or warranty, information from experiments and information that might be performance of the Company is not guaranteed. The express or implied, is made or given by or on behalf of the considered forward-looking. While these forward-looking Company does not undertake any obligation to update these Company, or any of its directors and affiliates or any other statements represent our current judgment based on current forward-looking statements to reflect events, circumstances, person, as to, and no reliance should be placed for any information, please be aware they are subject to risks and or changes in expectations after the date hereof or to reflect purposes whatsoever on, the fairness, accuracy, uncertainties as development progresses that could cause the occurrence of subsequent events. No representations or completeness or correctness of, or any errors or omissions in, actual results to differ materially. These materials also contain warranties are made as to the accuracy or reasonableness of the information contained herein or any other information, material, non-public information. In addition, these materials such assumptions or projections or the forward-looking whether written or oral, transmitted or made available to you contain forward-looking statements that are, by their nature, statements based thereon. herewith. The Company name and all related names, logos, subject to significant risks and uncertainties. In these product and service names and designs included in these materials, the words “will,” “anticipate,” “expect,” “plan,” This presentation does not constitute or form part of, and materials are trademarks of the Company or its affiliates or “potential,” and similar expressions identify forward-looking should not be construed as, directly or indirectly, any offer or licensors. All other names, logos, product and service names, statements. Such forward-looking statements necessarily intimation or inducement to sell or issue or an offer or any and designs included in these materials are the trademarks of involve known and unknown risks and uncertainties, which solicitation of any offer, to purchase or sell any securities, as their respective owners. The distribution of these materials in may cause actual performance and financial results in future defined. The information contained here is not a prospectus, certain jurisdictions may be restricted or affected by the laws periods to differ materially from any projections of future statement in lieu of prospectus, advertisement, or any other of such jurisdictions. To the fullest extent permitted by performance or result expressed or implied by such forward- offer. It is not the Company’s intention to provide, and you applicable law, the Company disclaims any responsibility or looking statements. Such forward-looking statements are may not rely on these materials as providing, a complete or liability for the violations of any such restrictions by any based on numerous assumptions regarding the Company’s comprehensive analysis of the Company’s financial position or person. present and future business strategies and the environment in prospects. The information contained in these materials has

2 Ichnos Sciences is a Clinical Stage Biotechnology Company at the Forefront of Innovation in Oncology

• Global footprint: U.S. and Switzerland, with over 200 colleagues across three sites Fully Integrated • Wholly-owned subsidiary of Glenmark, with plans to separate in the future Biotech • Accomplished management team with proven track record in oncology drug discovery, development and commercialization

• Core capabilities in biologics (discovery, antibody engineering, CMC, clinical development) • Focus on Immuno-oncology: Strategic • Multispecific immune and non-immune cell engagers antibodies Approach • Disease-centric

• Strategic efforts in small molecules through service agreement with Glenmark Pharmaceuticals Ltd

• Proprietary BEAT® antibody engineering platform represents the discovery engine to sustain innovation and drive long-term growth: Novel BEAT® • Next-generation multispecific immune and non-immune cell engager antibodies that can engage multiple targets Platform simultaneously

• Broad oncology pipeline with six programs, including two clinical-stage assets in multiple myeloma (ISB 1342) and HER2+ breast Deep Pipeline cancer (ISB 1302) • Beyond oncology, pipeline of potential first-in-class therapeutics addressing autoimmune disease

*BEAT® : Bispecific Engagement by Antibodies based on the T cell Receptor ICHNOS SCIENCES | DO NOT COPY OR DISTRIBUTE 3 Ichnos: Highly Experienced Biotech Leadership Team

Management

ALESSANDRO RIVA, M.D. PATRICK FLANIGAN, KALA SUBRAMANIAN,Ph.D. GABRIELA GRUIA, M.D. M. LAMINE MBOW, Ph.D. Chief Executive Officer III Chief of Staff, Head of Chief Development Officer Head of New Biologics Entity Strategic & Business Chief Financial Officer Discovery Development & Licensing

NEELUFAR ROBERTO GIOVANNINI, MARTIN WILSON ISABEL CARMONA GRACE MAGUIRE, MBA MOZAFFARIAN,M.D.,Ph.D. Ph.D. General Counsel Chief Human Resources Officer Head of Communications Head of Clinical Sciences, Head of CMC Development and Corporate Affairs Autoimmune Disease, and Pain

Board of Directors Glenn Saldanha Bernard Munos Dennis V S Mani Jayaram Marcela David Lubner Lawrence Chairman & Non-Executive Purcell Board Member & Philkana Maus, M.D., Non-Executive Olanoff, Managing Director Non-Executive Global CFO of GPL President & Ph.D. Director M.D., Ph.D. Director, Director Global CHRO of Non-Executive Non-Executive Glenmark GPL Director Director Pharmaceuticals

Also a member of Board of Directors ICHNOS SCIENCES | DO NOT COPY OR DISTRIBUTE 4 Ichnos Is Advancing a Differentiated Pipeline with Potential First- and Best-in-Class Assets

Candidate Target Preclinical Phase 1 Phase 2 Status

Oncology

ISB 1342 CD38 x CD3 BEAT® bispecific antibody Relapsed/Refractory Multiple Myeloma Phase 1 Enrolling

® Relapsed/Refractory ISB 1908 CD38 x CD3 BEAT bispecific antibody Multiple Myeloma IND Enabling Activity

ISB 1909 BEAT® T-cell engager Undisclosed Discovery

® Hematologic ISB 1442 CD38 x CD47 BEAT bispecific antibody Malignancies IND Enabling Activity

ISB 1302 HER2 x CD3 BEAT® bispecific antibody Metastatic HER2+ Breast Cancer Phase 1 Enrolling

ISC XXX HPK1 inhibitor small molecule Undisclosed IND Enabling Activity

Autoimmune Phase 2b fully enrolled ISB 830 OX40 antagonist monoclonal antibody Atopic Dermatitis Part 2 (high dose arm) data in AD end of 2020 Autoimmune ISB 880 IL-1RAP antagonist monoclonal antibody Disease IND Enabling Activity

Pain 2H:2020: Start formulation study in healthy Diabetic Peripheral Neuropathy ISC 17536* TPRA1 antagonist small molecule volunteers

Note: Assets that were previously identified as GBR and GRC are now identified as ISB (for biologics) and ISC (for small molecules), respectively. *During a Type C meeting with FDA in March 2020, agreement was reached regarding the nonclinical plan to enable a randomized, double-blind, placebo-controlled, Phase 2b, dose-range-finding study for painful DPN. These nonclinical studies are ongoing/planned, and a formulation study in healthy volunteers is expected to start in the second half of CY 2020. Ichnos Sciences will complete preclinical and clinical work required to start the Phase 2b study and then plans to out-license the compound. Denotes Potential Partnering Candidate ICHNOS SCIENCES | DO NOT COPY OR DISTRIBUTE 5 BEAT Platform Ichnos BEAT® Platform Positioned Among Most Innovative T-Cell Engager Formats in Development

1st Generation 2nd GenerationGeneration 3rd Generation Fragment based Formats Fab-Fragment based Formats Fab-Fab based Formats Genetic fusion of a Fab and an antibody Technology for light chain pairing (random Genetic fusion of 2 antibody fragments- scFvs, fragment- scFv or dAb, with Fc – requires heavy pairing of light chains upon co-transfection) with or without Fc chain pairing technology added to heavy chain pairing technology, with Fc

• No Fc Region: Short half life requiring • Mixed format approach with longer half • Natural antibody format, longer half continuous infusion life than the fragment based format life than the fragment-based format without Fc without Fc • Fc Region (silenced): Longer half life • Common light chain technology: allowing for weekly dosing, requires • Improved druggability and developability Enhanced druggability and heavy chain pairing technology o • Rapid engineering developability (random pairing of heavy chains upon Best suited for multispecific co-transfection) • Not optimal for multispecific antibodies o antibodies • Limited target druggability and o Opens design space to select developability best drug candidates • Not suited for multispecific antibodies o Allows for easy scale up

Ichnos BEAT® 1.0 platform Ichnos BEAT® 2.0 platform

Domain antibody (dAb) is an antibody fragment consisting of a single monomeric variable antibody domain that is able to bind an antigen; Antigen-binding fragment (Fab) is the natural region on an antibody that binds to an antigen. It is composed of one constant and one variable domain of each of the heavy and the light chain; Fragment crystallizable (Fc) region is the tail region of an antibody that interacts with cell surface receptors called Fc receptors including the neonatal Fc receptor, a key determinant in maintaining and prolonging antibody plasma half-life; Single chain fragment variable (scFv) is a genetic fusion of the heavy and light chain variable domains of an antibody that is able to bind an antigen. ICHNOS SCIENCES | DO NOT COPY OR DISTRIBUTE 7 Key Challenges in Engineering Bi/Trispecific Antibodies: A Tale of Dismantling and Reassembling Antibodies

Heavy chain 2 Heavy chain 1 • Making bispecific antibodies in the natural antibody requires the optimal assembly of four different chains 4 DIFFERENT CHAINS with minimal engineering Light chain 1 Light chain 2 COMPETITIVE LANDSCAPE COMPETITIVE • Step 1: Assemble heavy chains via heavy chain HEAVY CHAIN technology TECHNOLOGY

Target 1 Target 2 • Step 2: Assemble light chains via light chain LIGHT CHAIN technology TECHNOLOGY

Target 3 • Optimal bispecific technologies allow for the design Target 1 of the trispecific antibodies by using the same UPGRADE TO TRISPECIFICS building blocks Target 2

ICHNOS SCIENCES | DO NOT COPY OR DISTRIBUTE 8 Ichnos Strategies for Engineering Bi/Trispecific Antibodies: BEAT® & TREAT™ - Two Potential Best-in-Class Platforms

Heavy chain 2 Heavy chain 1 • Making bispecific antibodies in the natural antibody requires the optimal assembly of four different chains with minimal 4 DIFFERENT CHAINS engineering Light chain 1 Light chain 2

• Step 1: Assemble heavy chains via natural TCR interface – ® HEAVY CHAIN buried mutations, i.e. not solvent exposed (BEAT interface) TECHNOLOGY

Target 1 Target 1 Target 2 Target 2 • Step 2: Assemble light chains via scFv formatting (BEAT® 1.0) ® LIGHT CHAIN or common light chain Fab technique (BEAT 2.0) BEAT 1.0 BEAT 2.0 TECHNOLOGY

Target 3 • Optimal design of trispecific antibodies by using the same Target 1 ™ Common variable light chain domain UPGRADE TO common light Fabs as building blocks (TREAT ) TRISPECIFICS Single-chain fragment variable (scFv) Target 2

IgG1 TCR constant alpha IgG3 TCR constant beta Skegro D. et al. J Biol Chem 2017; 292(23):9745-59 Ollier R. et al. mAbs 2019; 11(8):1464-1478 Stutz C. and Blein S. J Biol Chem TREAT 2020; 295(28): 9392-9408

BEAT® : Bispecific Engagement by Antibodies based on the T cell Receptor TCR: T Cell Receptor TREAT™: Trispecific Engagement by Antibodies based on the T cell Receptor ICHNOS SCIENCES | DO NOT COPY OR DISTRIBUTE 9 scFv: single-chain Fragment variable Ichnos BEAT® Platform Is Positioned to be Readily Developable as Bispecific & Multispecific Antibodies

® BEAT® 2.0 (2+1) BEAT® 1.0 BEAT 2.0 (1+1)

Fab scFv

TRISPECIFIC(TREAT™) • Versatile and quick to engineer • “Plug & Play” approach to antibody design via common • Not suited for trispecific format light chain Fab technology • Platform versatility accelerates the advancement of IgG1 TCR constant alpha novel targets IgG3 TCR constant beta • Larger therapeutic window can be engineered (2+1)

Common variable light chain domain • Technology supports the development of multispecific antibodies

BEAT® : Bispecific Engagement by Antibodies based on the T cell Receptor TREAT™: Trispecific Engagement by Antibodies based on T cell Receptor ICHNOS SCIENCES | DO NOT COPY OR DISTRIBUTE 10 BEAT® 2.0: Structure-Activity Optimization of Bi/Trispecific Antibodies to Unlock New Biology

Common light chain Fabs Bi-/multispecific antibodies are Two different common light readily translate into bi- correctly assembled, express chain Fab discovery platforms /multispecific antibodies at high levels & efficiently allows for large epitope without the need of further purified from a single coverage engineering chromatography step

Enables deep exploration of the bi/multispecific design space to optimize drug candidates and unlock new biology (e.g., T-cell, NK cells, macrophage engagers) by testing: + Affinity: low-medium-high combinations + Epitope: target/test several epitopes + Architecture: avidity, immune synapse size + Fc function: T cell: silent; non T cell: active - enhanced

ICHNOS SCIENCES | DO NOT COPY OR DISTRIBUTE 11 Oncology Compounds in Clinical Development Immune Cell Engagers and Cell Therapies Are Emerging as the Next Wave of Transformative Medicines in Oncology

1940s 1990s 2010s Present First chemotherapy First targeted antibody Checkpoint inhibitors CD19 CAR-T approved CD19 x CD3 approved approved therapy approved approved Other CAR-T in development Other targets: BCMA x CD3; CD20 x CD3,CD38 x CD3 1 4

Drug antibody Leukapheresis Modified T-Cell Infusion Tumor B Cell

2 3 Any T Cell

T-cell Activation/ Modified T-Cell Transduction Expansion

Chemotherapy Targeted Therapies Immuno-Oncology Cell Therapies Immune Cell Engagers Indiscriminate – kills Target receptor/molecular Checkpoint and innate Re-engineered T cells Bispecific Antibodies healthy and cancer cells oncogenic drivers immunity modulators Multispecific Antibodies

CAR: Chimeric Antigen Receptor Sudhakar A. J Cancer Sci Ther 2009;1:1-4; Checkpoint inhibitors image: Reprinted from Immunity, Vol 39, Chen DS, Mellman I., Oncology Meets Immunology: ICHNOS SCIENCES | DO NOT COPY OR DISTRIBUTE 13 The Cancer-Immunity Cycle, Pages 1-10, Copyright 2013, with permission from Elsevier. ISB 1342 ISB 1342(CD38 x CD3)Bispecific Antibody: Potential First- in-Class Therapy in Relapsed/Refractory Multiple Myeloma

Key Attributes ISB 1342 (CD38 x CD3) ® bispecific antibody BEAT 1.0 • CD38 is expressed on the surface of multiple myeloma cells and is a validated target • ISB 1342 is a bispecific antibody that redirects T lymphocytes to kill CD38-expressing tumor cells in MHC-antigen-independent manner CD38 Tumor cell • ISB 1342 binds to a proprietary anti-CD38 epitope, which is different from that of daratumumab or isatuximab CD3 • ISB 1342 is designed to overcome: T cell • Daratumumab resistance by killing low CD38-expressing tumor cells • Resistance to CDC and ADCC mediated by daratumumab

• Granted orphan drug designation in 2019 • Phase 1 dose escalation and expansion study, including weekly dosing, is ongoing BEAT interface MHC: Major histocompatibility complex, CDC: Complement-Dependent Cytotoxicity ADCC: Antibody-Dependent Cell-mediated Cytotoxicity ICHNOS SCIENCES | DO NOT COPY OR DISTRIBUTE 15 ISB 1342 Induces More Potent Re-directed Lysis Against Various CD38-Expressing Tumor Cells Compared to Daratumumab In Vitro

CD3+ T cell Re-directed Lysis

CD38+ Tumor Cell

CD38 expression level

By co-engaging TCR/CD3ε on T lymphocytes and CD38 on tumor cells, ISB 1342 induces the formation of an immunological synapse between T cells and tumor cells and the re-directed lysis of tumor cells (left panel). The potency of daratumumab and ISB 1342 to kill in vitro tumor cells expressing low, intermediate and high levels of CD38 was compared in a multiple mode of action killing assay that combines Antibody-Dependent Cell-mediated Cytotoxicity (ADCC), Complement-Dependent Cytotoxicity (CDC) and re-directed cell lysis (right panel).

Data on file. Clinical significance unknown.

ICHNOS SCIENCES | DO NOT COPY OR DISTRIBUTE 16 ISB 1342 Induces More Potent Tumor Cell Killing In Vitro Compared to Daratumumab

ISB1342 Irrelevant BEAT Daratumumab Control antibody

ISB1342 Irrelevant Daratumumab Control ISB1342 Irrelevant Daratumumab Control ISB1342 Irrelevant Daratumumab Control BEAT antibody BEAT antibody BEAT antibody

CD69 Ki-67 Granzyme B Potency of ISB 1342 and daratumumab to kill NCI-H929 cells (CD38 intermediate tumor cells) in vitro in a multiple mode of action killing assay (left panel). Specific tumor cell killing was measured at t=48h, isotype control antibody and irrelevant BEAT with dummy CD3 and CD38 binders were used as a negative controls. T-cell activation in response to maximum dose of ISB 1342 and daratumumab was measured in the same assay at t=48h. (right panel)

Data on file. Clinical significance unknown.

ICHNOS SCIENCES | DO NOT COPY OR DISTRIBUTE 17 Soluble CD38 Does Not Impact ISB 1342 Killing Potency In Vitro

sCD38 (ng/ml) EC50 +/- SD of Killing (pM) 0 1.59 +/- 0.38

0.35 1.67 +/- 0.15

2.8 1.73 +/- 0.43

soluble CD38 2.8 ng/ml 0.35 ng/ml 0 ng/ml

Re-directed cell lysis assay performed in the presence of KMS-12-BM cells and varied concentrations of soluble CD38 reflecting the concentration of soluble CD38 in the peripheral blood (0.35 ng/ml) or in the bone marrow (2.8 ng/ml) of advanced-stage multiple myeloma patients. Specific killing was measured at t=72h. Irrelevant BEAT with dummy CD3 and CD38 binders was used as a negative control.

Data on file. Clinical significance unknown.

ICHNOS SCIENCES | DO NOT COPY OR DISTRIBUTE 18 ISB 1342 Effectively Controls Tumor Growth In Vivo Associated With Production of Cytolytic Markers

NOD-SCID mice were xenografted subcutaneously with human peripheral blood mononuclear cells and Daudi cells. ISB 1342 or daratumumab were injected intravenously weekly when tumor reached 100 mm3 and tumor growth monitored over two weeks (left panel). Soluble immune factors were quantified in dissociated tumors one week post-treatment (right panel).

Data on file. Clinical significance unknown.

ICHNOS SCIENCES | DO NOT COPY OR DISTRIBUTE 19 ISB 1302 ISB 1302(HER2 x CD3): Bispecific Antibody Positioned to Address Unmet Medical Needs in Metastatic HER2+ Breast Cancer

Key Attributes ISB 1302 (HER2 x CD3) ® bispecific antibody BEAT 1.0 • HER2 is expressed on the surface of numerous cancers, including breast cancer, and is the target of several highly effective therapies • ISB 1302 is designed to redirect T cell mediated killing of HER2- CD3 expressing tumor cells in MHC-antigen independent manner T cell • ISB 1302 binds to the same HER2 epitope as trastuzumab HER2 • ISB 1302 has demonstrated effective tumor killing in preclinical Tumor cell models. In vivo model to evaluate the impact of ISB 1302 on trastuzumab-resistant tumor lines is under development

• Ongoing phase 1 trial in patients with HER2 metastatic breast cancer; dose escalation and expansion including weekly and bi-weekly dosing

BEAT interface MHC: major histocompatibility complex

ICHNOS SCIENCES | DO NOT COPY OR DISTRIBUTE 21 ISB 1302 Killing Potency In Vitro Is Associated With the Level of HER2 Expression on Target Cells EC50 of cell killing killing cell of EC50

HER2 0 1 2 3+ Expression level

Re-directed cell lysis assay performed in the presence of peripheral mononuclear cells and cardiomyocytes or various HER2-expressing tumor cells. EC50 of specific killing at t=72h is shown for each cell type.

Data on file. Clinical significance unknown.

ICHNOS SCIENCES | DO NOT COPY OR DISTRIBUTE 22 ISB 1302 Kills Trastuzumab-Resistant Breast Cancer Tumor Cells In Vitro

100 60 ISB1302 s g

Trastuzumab l l n i l e l i 50 Irrelevant BEAT c k 40

T c i

f Isotype i + c 8 e D p 0 S C

-4 -2 0 2 f 20 % o log of concentration (nM) -50 %

0 CD25 CD69 Granzyme B IFN-g TNF-a Ki-67 100000

10000 Re-directed tumor cell lysis assay performed with peripheral blood mononuclear cells, BT-474.5 trastuzumab-resistant breast tumor cells and increasing l 1000 m / g

concentrations of ISB 1302 or trastuzumab (t=72h, left panel). Isotype control p 100 antibody and irrelevant BEAT with dummy CD3 and HER2 binders were used as a negative controls. T-cell activation (top right panel) and release of soluble 10 cytokines and cytotoxic markers (bottom right panel) in response to maximum 1 dose of ISB 1302 were quantified at t=72h. IL-6 IL-10 Granzyme B IFN-g Perforin

Data on file. Clinical significance unknown.

ICHNOS SCIENCES | DO NOT COPY OR DISTRIBUTE 23 ISB 1302 Killing Potency Is Minimally Impacted by Soluble HER2

Re-directed cell lysis assay performed with BT-474.5 trastuzumab-resistant breast tumor cells in the presence of peripheral blood mononuclear cells and 100 ng/ml of soluble HER2. This concentration of soluble HER2 reflects the one detected in the peripheral blood of advanced-stage breast cancer patients. Specific killing was measured at t=72h in the presence of ISB 1302 (left panel) and trastuzumab (right panel). Isotype control antibody and irrelevant BEAT with dummy CD3 and HER2 binders were used as a negative controls.

Data on file. Clinical significance unknown.

ICHNOS SCIENCES | DO NOT COPY OR DISTRIBUTE 24 ISB 1302 Efficiently Controls Tumor Growth In Vivo

IS B 1 3 0 2 a t 0 .5 u g /m g h P B M C d o n o r 2

Control vehicle group 8 0 0 ISB 1302-treated group ) ) 3

3 6 0 0

4 0 0

2 0 0 Tumor volume (mm Tumor volume (mm 0 0 2 0 4 0 6 0 D a y s a f t e r x e n o g r a f t

NOD-SCID mice were xenografted subcutaneously with human peripheral blood mononuclear cells and NCI-N-87 cells. ISB 1302 was injected intravenously weekly at 0.05 mg/kg when tumor reached 100-200 mm3. Tumor growth was monitored over 50 days (n=5 mice for control and treated group). One representative experiment out of two, with two distinct PBMC donors, is shown.

Data on file. Clinical significance unknown.

ICHNOS SCIENCES | DO NOT COPY OR DISTRIBUTE 25 Autoimmune / Pain Compounds in Clinical Development ISB 830: Potential First-in-Class OX40 Antagonist for Autoimmune Diseases

Key Attributes Signaling through OX40 increases disease pathophysiology by enhancing T effector activation • OX40 (CD134) is a key T cell costimulatory molecule and production of proinflammatory cytokines involved in autoimmunity and inflammation • ISB 830 binds to OX40 on the surface of activated T cells, preventing T effector proliferation and cytokine production • Phase 2b trial in moderate-to-severe atopic dermatitis is ongoing

- Results from Part 1: The primary endpoint of EASI score, % change from baseline to Week 16, was achieved for the highest dose tested versus placebo. A numerical improvement was seen in the secondary endpoints of EASI-75 and IGA; however, the differences were not statistically different from placebo. ISB 830 was safe and well- tolerated in Part 1, with adverse event rates similar to those in the placebo group

- Part 2: Topline results of part 2 (higher dose of ISB 830 versus placebo) are expected 4Q: 2020 • US IND active to conduct studies of ISB 830 in additional indications, including rheumatoid arthritis (RA)

EASI: Eczema Area and Severity Index

ICHNOS SCIENCES | DO NOT COPY OR DISTRIBUTE 27 ISC 17536: Novel Transient Receptor Potential Ankyrin 1(TRPA1) Antagonist for Painful Diabetic Peripheral Neuropathy(DPN)

Key Attributes ISC 17536: An Oral, TRPA1 Antagonist

• TRPA1 (transient receptor potential ankyrin 1) is a key ion • TRPA1 is a receptor on channel responsible for pain sensation by small nerve small nerve fibers fibers throughout the body • Implicated in several painful neuropathic • ISC 17536 is a selective antagonist of TRPA1 conditions • Completed a randomized, placebo-controlled, dose-range- EXCITATION finding phase 2a proof-of-concept trial in patients with CA 2+ NA painful diabetic peripheral neuropathy: + - primary endpoint was not met in the overall study population SENSORY NERVES Pain PAIN STIMULI Signal - clinically and statistically significant reduction in pain was achieved in a prespecified subpopulation of patients with preserved small nerve fiber function TRPA1 • Ichnos will evaluate out-licensing opportunities for ISC Pain stimuli (yellow circles) 17536 to align with strategic priorities activate TRPA1 ion channels in sensory nerves, leading to excitation and transmission of pain signals

ICHNOS SCIENCES | DO NOT COPY OR DISTRIBUTE 28 Ichnos Sciences is a Clinical Stage Biotechnology Company at the Forefront of Innovation in Oncology

• Strategic efforts in small molecules through service agreement with Glenmark Pharmaceuticals Ltd

*BEAT® : Bispecific Engagement by Antibodies based on the T cell Receptor

ICHNOS SCIENCES | DO NOT COPY OR DISTRIBUTE 29